filovirida
famili
consist
ebolaviru
marburgviru
cuevaviru
genera
histor
ebola
viru
ebov
zair
ebolaviru
speci
common
deadli
filovirus
therefor
research
commun
larg
focus
develop
ebov
anim
model
tool
vaccin
therapeut
success
produc
sever
compound
reach
late
stage
clinic
trial
light
success
possibl
extend
research
toward
discoveri
panfiloviru
vaccin
therapeut
howev
anim
model
suscept
ebolavirus
speci
need
establish
first
order
directli
evalu
whether
panfiloviru
vaccin
therapeut
provid
crossprotect
nonhuman
primat
nhp
close
mimic
clinic
manifest
filoviru
infect
human
provid
invalu
insight
pathogenesi
cours
filoviru
diseas
yet
due
ethic
cost
space
restraint
accompani
nhp
studi
smaller
anim
model
mice
guinea
pig
typic
first
choic
initi
filoviru
drug
vaccin
pathogenesi
studi
although
wildtyp
filovirus
caus
signific
diseas
adult
immunocompet
rodent
virus
adapt
rodent
virul
lethal
observ
even
though
rodent
model
reproduc
hallmark
clinic
sign
filoviru
diseas
rel
easeofus
low
cost
make
attract
first
option
evalu
antivir
prophylact
therapeut
studi
focus
character
ferret
novel
intermedi
anim
model
sudan
viru
sudv
member
sudan
ebolaviru
speci
bridg
experiment
result
rodent
nhp
sudv
endem
south
sudan
republ
uganda
highli
lethal
human
averag
case
fatal
rate
sudv
outbreak
uganda
second
largest
filoviru
outbreak
date
result
death
total
case
cfr
unlik
ebov
compar
lack
experiment
medic
countermeasur
sudv
anim
model
sudv
begin
emerg
shown
alphabetagamma
interferon
receptor
knockout
mice
suscept
wildtyp
sudv
infect
addit
recent
character
guinea
pigadapt
variant
uniformli
lethal
guinea
pig
howev
better
strategi
would
screen
candid
drug
immunocompet
small
anim
use
wildtyp
sudv
avoid
need
develop
rodentadapt
model
progress
studi
nhp
ferret
pig
initi
emerg
excel
model
human
respiratori
diseas
lung
physiolog
close
mimic
human
interestingli
among
character
mani
respiratori
viru
infect
variou
influenza
strain
respiratori
syncyti
viru
nipah
viru
coronavirus
virus
also
recent
test
ferret
includ
hepat
e
three
speci
ebolaviru
investig
whether
ferret
suscept
wildtyp
sudv
group
six
anim
inocul
via
intramuscular
im
intranas
rout
sudv
backtit
dose
x
stock
viru
origin
isol
acutephas
blood
patient
outbreak
sudan
passag
guinea
pig
twice
vero
cell
sequenc
passag
step
chang
comparison
origin
patient
sampl
addit
sequenc
viru
recov
ferret
time
death
differ
clinic
isol
input
viru
indic
viru
adapt
fact
wildtyp
day
postinfect
well
day
euthanasia
day
clinic
assess
perform
blood
sampl
taken
complet
blood
count
differenti
quantif
serum
biochemistri
paramet
coagul
factor
viremia
im
group
equal
suscept
infect
wildtyp
sudv
succumb
diseas
median
surviv
time
day
group
figur
anim
given
clinic
score
everi
day
base
visibl
diseas
symptom
chang
weight
temperatur
activ
food
water
intak
respir
well
urin
fece
sign
ill
observ
begin
day
includ
decreas
activ
food
water
intak
respir
rate
increas
notabl
absenc
urin
sever
ill
anim
diarrhea
observ
earli
onset
ill
dryno
fece
preval
anim
advanc
sudv
diseas
fever
observ
begin
day
post
infect
figur
decreas
weight
day
figur
viremia
detect
day
group
figur
rtqpcr
day
supplementari
figur
similar
peak
titer
reach
intranas
group
trend
toward
slightli
higher
genom
copi
intramuscular
group
later
timepoint
day
howev
differ
reach
statist
signific
cours
diseas
substanti
affect
absolut
count
white
blood
cell
figur
lymphocyt
supplementari
figur
monocyt
supplementari
figur
neutrophil
supplementari
figur
red
blood
cell
supplementari
figur
platelet
number
drop
sharpli
im
group
begin
day
post
infect
figur
abnorm
blood
also
appar
day
postinfect
im
infect
induc
decreas
albumin
calcium
level
increas
globulin
alkalin
phosphatas
alanin
aminotransferas
amylas
supplementari
figur
maintain
stabl
total
level
protein
addit
im
group
saw
increas
sodium
level
variabl
pattern
blood
urea
nitrogen
phosphoru
potassium
intranas
group
exhibit
increas
blood
urea
nitrogen
bilirubin
phosphoru
variabl
level
glucos
sodium
supplementari
figur
overal
paramet
indic
day
post
infect
multipl
organ
coagul
system
malfunct
anim
like
react
system
viral
infect
inflamm
hemorrhag
also
measur
presenc
coagul
factor
blood
presenc
thrombin
fibrinogen
blood
gener
indic
coagul
result
activ
either
intrins
extrins
coagul
pathway
assay
thrombin
plasma
sampl
ferret
spike
known
amount
thrombin
activ
blood
clot
control
preinfect
sampl
faster
clot
time
endpoint
sampl
indic
addit
thrombin
present
figur
order
measur
fibrinogen
level
standard
curv
produc
use
control
plasma
sampl
contain
serial
dilut
known
amount
fibrinogen
clot
time
measur
ferret
sampl
fibrinogen
level
calcul
base
standard
curv
figur
ferret
fold
higher
level
fibrinogen
time
death
compar
preinfect
measur
activ
partial
thromboplastin
time
aptt
determin
activ
intrins
coagul
pathway
factor
xii
xi
ix
viii
x
v
ii
figur
ratio
display
result
indic
activ
ferret
plasma
sampl
elev
compar
manufactur
control
plasma
sampl
prothrombin
time
pt
indic
percentag
normal
activ
ferret
sampl
compar
manufactur
control
plasma
sampl
correl
involv
extrins
coagul
pathway
factor
ii
v
vii
x
valu
decreas
im
group
time
death
figur
investig
viral
shed
sudv
infect
oral
rectal
swab
well
nasal
wash
collect
anim
use
determin
viru
variou
time
point
rtqpcr
viru
detect
earlier
gener
higher
ferret
receiv
inocul
compar
im
infect
includ
nasal
wash
im
geqml
geqml
supplementari
figur
oral
swab
im
geqml
geqml
supplementari
figur
contrast
rectal
shed
detect
anim
per
group
geqml
supplementari
figur
order
assess
system
viral
spread
differ
organ
liver
spleen
kidney
heart
lung
harvest
time
death
assess
viral
titer
im
group
sudv
spread
system
infect
major
intern
organ
anim
organ
im
group
consist
reach
titer
geqg
tissu
although
averag
geq
group
slightli
higher
figur
similarli
tissu
contain
infecti
viru
measur
titer
group
gener
higher
im
group
particularli
lung
figur
im
inocul
group
sever
histopatholog
chang
observ
tissu
associ
presenc
sudv
antigen
lung
im
inocul
anim
lesion
mild
character
slight
increas
inflammatori
cell
within
alveolar
wall
figur
antigen
occasion
detect
primarili
within
macrophagelik
cell
perivascular
area
figur
contrast
lung
inocul
anim
show
multifoc
diffus
sever
bronchointerstiti
pneumonia
figur
abund
posit
immunostain
figur
liver
group
moder
sever
patholog
diffus
vacuolar
degener
loss
hepatocyt
lead
disrupt
normal
architectur
well
infiltr
inflammatori
cell
portal
area
figur
group
viral
antigen
could
detect
within
hepatocyt
periport
area
figur
howev
viral
antigen
abund
ininocul
group
spleen
im
group
signific
lesion
increas
cellular
splenic
cord
howev
one
anim
lymphocytolysi
figur
group
similar
lesion
observ
howev
addit
multifoc
area
necrosi
figur
abund
viral
antigen
observ
within
macrophagelik
cell
throughout
red
pulp
area
multifoc
within
germin
centr
figur
howev
viral
antigen
abund
group
lesion
observ
within
kidney
howev
im
group
occasion
foci
interstiti
nephriti
figur
associ
presenc
viral
antigen
figur
signific
lesion
observ
heart
either
group
howev
small
amount
viral
antigen
detect
within
capillari
occasion
within
cardiomyocyt
endocardium
choos
develop
anim
model
close
mimic
human
physiolog
cours
diseas
import
step
toward
develop
effect
prophylact
therapeut
option
although
rodent
small
anim
model
suitabl
larg
antivir
screen
anim
model
close
resembl
hallmark
human
diseas
imper
followup
studi
confirm
believ
reliabl
preclin
result
test
human
studi
demonstr
im
rout
sudv
inocul
lead
viremia
system
organ
infect
dysfunct
viral
shed
similar
time
death
evidenc
follow
indic
increas
viremia
organ
viral
load
indic
uncontrol
viru
replic
spread
decreas
wbc
lym
count
indic
compromis
immun
increas
fibrinogen
aptt
tt
decreas
plt
pt
indic
dissemin
intravascular
coagulopathi
overal
kinet
viral
infect
similar
two
group
viral
load
consist
higher
infect
anim
appear
earlier
nasal
oral
swab
well
lung
tissu
sudv
infect
ferret
share
mani
similar
sudv
diseas
model
knockout
mice
guinea
pig
nhp
addit
human
tabl
fever
weight
loss
leukopenia
decreas
plt
count
extern
haemorrhag
observ
anim
model
howev
haemorrhag
observ
human
patient
rash
observ
anim
howev
document
anoth
sudv
ferret
studi
sometim
observ
nhp
seen
human
coagulopathi
observ
anim
model
knockout
mice
guinea
pig
ferret
addit
human
increas
alp
alt
ast
bun
decreas
ca
tp
level
observ
ferret
nhp
dysregul
cytokin
increas
level
nitric
oxid
observ
ferret
human
tabl
logist
ferret
demand
term
hous
space
mainten
cost
compar
rodent
addit
immunolog
reagent
avail
studi
tcell
respons
ferret
although
sever
previous
develop
pillet
et
al
altern
human
reagent
use
success
studi
could
valid
purpos
futur
howev
ferret
model
also
provid
sever
major
advantag
particular
valu
abil
use
clinic
isol
without
need
prior
adapt
three
ebolavirus
test
anoth
studi
sudv
speci
use
current
studi
highli
infecti
uniformli
lethal
previous
possibl
without
adapt
except
nonhuman
primat
studi
also
add
sever
valuabl
uniqu
aspect
character
sudvinfect
ferret
exampl
compar
two
differ
common
rout
infect
repres
mucos
infect
thought
common
natur
infect
rout
among
peopl
wherea
im
inocul
similar
needlestick
injuri
lab
interestingli
data
demonstr
rate
spread
viru
similar
rout
infect
except
nasal
oral
lung
tissu
replic
viru
approxim
higher
titer
also
includ
novel
data
regard
viral
shed
mucos
tissu
demonstr
ferret
may
hold
promis
futur
transmiss
studi
current
reli
sole
use
nonhuman
primat
although
directli
test
transmiss
studi
observ
high
level
oral
nasal
viral
shed
suggest
ferret
may
readili
transmit
ferret
via
rout
abil
studi
ebolaviru
transmiss
without
use
nonhuman
primat
would
highli
benefici
term
cost
feasibl
ethic
approv
overal
develop
ferret
model
ebolavirus
provid
use
intermedi
anim
model
may
abl
bridg
rodent
nonhuman
primat
studi
well
provid
new
mean
studi
viral
transmiss
test
vaccin
therapeut
anim
work
studi
perform
biosafeti
facil
canadian
scienc
centr
human
anim
health
cschah
winnipeg
canada
experi
approv
anim
care
committe
cschah
accord
guidelin
canadian
council
anim
care
per
protocol
anim
acclimat
day
prior
infect
given
food
water
ad
libitum
monitor
twice
daili
environment
enrich
also
provid
cage
throughout
durat
studi
twelv
sixmonth
old
femal
ferret
mustela
putoriu
furo
purchas
marshal
bioresourc
new
york
usa
receiv
anticoccidi
vaccin
distemp
viru
rabi
viru
prior
commenc
experi
ferret
randomli
assign
two
group
infect
either
intramuscularli
im
intranas
use
target
challeng
dose
x
sudv
isol
bonefac
viru
stock
use
origin
isol
acutephas
blood
patient
outbreak
sudan
passag
guinea
pig
twice
cell
genbank
access
backtitr
indic
anim
receiv
x
infect
anim
monitor
daili
sign
diseas
blood
drawn
everi
second
day
determin
viral
load
evalu
biochem
marker
serum
biochemistri
evalu
day
postinfect
vetscan
blood
analyz
abaxi
usa
use
heparin
blood
investig
complet
blood
cell
count
whole
blood
analyz
use
vetscan
hematolog
system
abaxi
usa
investig
coagul
citrat
plasma
use
determin
content
fibrinogen
amount
activ
partial
thromboplastin
aptt
gener
percent
partial
thromboplastin
use
instrument
diagnostica
stago
assay
run
per
manufactur
instruct
total
rna
extract
blood
well
oral
rectal
nasal
swab
use
qiaamp
viral
rna
minikit
qiagen
total
rna
extract
organ
biopsi
use
rneasi
kit
accord
manufactur
instruct
qiagen
revers
transcriptionquantit
pcr
roch
lightcycl
rna
master
hydrolysi
probe
kit
use
determin
viral
titer
follow
paramet
primer
probe
l
gene
sudvlforward
sudvlrevers
sudvlprobefam
pcr
program
minut
second
cycl
second
second
cycl
cell
grown
confluenc
infect
serial
dilut
whole
blood
h
inoculum
remov
cell
overlaid
fresh
mem
plu
fb
day
postinfect
plate
assess
lowest
dilut
well
exhibit
cytopatholog
per
millilit
calcul
accord
reedmuench
method
data
analyz
use
graphpad
prism
softwar
surviv
compar
use
log
rank
test
pvalu
pvalu
pvalu
pvalu
ns
signific
tissu
fix
neutral
phosphat
buffer
formalin
routin
process
section
stain
hematoxylin
eosin
histopatholog
examin
immunohistochemistri
ihc
paraffin
tissu
section
quench
minut
aqueou
hydrogen
peroxid
epitop
retriev
use
dako
target
retriev
solut
dako
usa
biocar
medic
decloak
chamber
primari
antibodi
appli
section
mous
monoclon
antiebola
sudan
use
dilut
thirti
minut
visual
use
hors
radish
peroxidas
label
polym
system
antimous
dako
usa
react
chromogen
diaminobenzidin
dab
section
counter
stain
gill
hematoxylin
